Navigation Links
Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference
Date:8/3/2009

FREMONT, Calif., Aug. 3 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will participate in multiple roles at IBC's Oligonucleotide Therapeutics: from Concept to Implementation Conference. The conference will take place August 3-5, 2009 in Boston, MA as part of IBC's Drug Discovery Week. Dr. Thompson has been appointed a member of the conference's scientific advisory board and will deliver the Conference Chair Opening Remarks. In addition, he will give a presentation and participate as a panel moderator.

Dr. Thompson's presentation, titled, "Design and Development of Synthetic siRNAs for Clinical Applications," will describe Quark's pipeline, which includes PF-04523655, a synthetic siRNA in Phase II clinical studies licensed by Pfizer in multiple ophthalmology indications, and QPI-1002, a synthetic siRNA in Phase I/II studies for two renal indications. The presentation will incorporate an update on Quark's clinical studies; a case study on the first siRNA administered systemically to man; and an overview of Quark's strategies to optimize synthetic siRNAs for clinical applications while avoiding off-target effects.

The Industry Leadership Forum panel Dr. Thompson will moderate is titled, "RNA Therapeutics - Are We Leveraging on the Promise?" It will cover the current state of development of siRNA, miRNA, antisense and aptamar therapeutics and examine how companies are capitalizing on the promise of the field. Panelists will include Paul Burke, Ph.D., Executive Director, RNA Therapeutics, Merck & Co., Inc.; Klaus Giese, Ph.D., Chief Scientific Officer, Vice President, Research, Silence Therapeutics AG; and Tod Woolf, Ph.D., President and CEO, RXi Pharmaceuticals Corporation.

Daniel Zurr, Ph.D., President and Chief Executive Officer of Quark, said, "Dr. Thompson's active and visible roles at the conference represent Quark's leadership position in the RNAi industry as the pioneer in systemic siRNA administration. We are at the forefront in oligonucleotide therapeutic development and look forward to discussing practical strategies and forward-looking approaches to support the current momentum in research and development in the field."

Dr. Thompson has been a leader in siRNA development for several years. Prior to joining Quark, he was Director of Research and Development at Genta, and previously Director of Biology Research at Sirna Therapeutics (formerly named Ribozyme Pharmaceuticals), which was acquired by Merck.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiovascular surgery and the prophylaxis of delayed graft function after kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from Alnylam Pharmaceuticals.

QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases. In addition, Quark has a broad pipeline of siRNA drug candidates based on novel structures developed internally. The Company expects to utilize the structures to develop additional RNAi drug candidates.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at www.quarkpharma.com

    Quark Pharmaceuticals, Inc.         The Ruth Group (investors / media)
    Juliana Friedman                    Sara Ephraim / Janine McCargo
    +972 89 30 5111                     (646) 536-7004 / 7033
    jfriedman@quarkpharma.com           sephraim@theruthgroup.com
                                        jmccargo@theruthgroup.com


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
2. Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
3. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
4. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
5. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
6. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
7. MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
8. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
9. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
10. Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
11. Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... today its affiliation with Tennessee Counseling Association. This new relationship allows ... the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is ...
(Date:6/26/2016)... N.J. (PRWEB) , ... June 27, 2016 , ... Quality ... sources, yet in many ways they remain in the eye of the beholder, according ... (EBO), a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... LAS VEGAS , June 26, 2016 ... movement to value-based care operating models within the health ... that enable greater financial efficiency , Deloitte offers ... address the key business issues impacting efficient cost optimization: ... alignment , These services facilitate better outcomes and ...
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology: